Author(s): Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al.
Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment.
METHODSA total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety.
Referred From: https://dx.doi.org/10.1056/NEJMoa1510665
Author(s): Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, et al.
Author(s): Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, et al.
Author(s): Rini BI, Shaw V, Rosenberg, Kim ST, Chen I
Author(s): Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, et al.
Author(s): Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, et al.
Author(s): Stoehr C, Burger M, Stoehr R, Bertz S, Ruemmele P, et al.
Author(s): Altavilla G, Fassan M, Busatto G, Orsolan M, Giacomelli L
Author(s): Leach FS, Koh M, Sharma K, McWilliams G, Talifero-Smith L, et al.
Author(s): Haugaard A, Pei Y, Fan Y, Cong Z
Author(s): Le D, Uram J, Wang H, Bartlett BR, Kemberling H, et al.
Author(s): Kelderman S, Schumacher TN, Kvistborg P
